Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $1.2 million.

  • Myriad Genetics' Tax Provisions rose 3333.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.8 million, marking a year-over-year decrease of 403333.33%. This contributed to the annual value of $3.8 million for FY2024, which is 24545.45% up from last year.
  • Latest data reveals that Myriad Genetics reported Tax Provisions of $1.2 million as of Q3 2025, which was up 3333.33% from -$100000.0 recorded in Q2 2025.
  • Myriad Genetics' 5-year Tax Provisions high stood at $15.2 million for Q3 2021, and its period low was -$35.9 million during Q4 2021.
  • For the 5-year period, Myriad Genetics' Tax Provisions averaged around -$4.5 million, with its median value being -$300000.0 (2024).
  • In the last 5 years, Myriad Genetics' Tax Provisions surged by 80000.0% in 2024 and then crashed by 2940000.0% in 2025.
  • Myriad Genetics' Tax Provisions (Quarter) stood at -$35.9 million in 2021, then skyrocketed by 72.7% to -$9.8 million in 2022, then surged by 88.78% to -$1.1 million in 2023, then surged by 409.09% to $3.4 million in 2024, then tumbled by 64.71% to $1.2 million in 2025.
  • Its Tax Provisions stands at $1.2 million for Q3 2025, versus -$100000.0 for Q2 2025 and -$29.3 million for Q1 2025.